Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 36% Improvement Relative Risk HCQ for COVID-19  Piñana et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective study in Spain (March - May 2020) Lower mortality with HCQ (not stat. sig., p=0.11) Piñana et al., Experimental Hematology.., Aug 2020 Favors HCQ Favors control

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Piñana et al., Experimental Hematology & Oncology, doi:10.1186/s40164-020-00177-z
Aug 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective study of 367 hematology patients with COVID-19 in Spain. Among 216 patients with very severe COVID-19, there was significantly lower mortality with azithromycin treatment. Mortality was also lower with HCQ, but without statistical significance.
risk of death, 36.0% lower, OR 0.64, p = 0.11, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Piñana et al., 25 Aug 2020, retrospective, Spain, peer-reviewed, median age 64.0, 46 authors, study period 1 March, 2020 - 15 May, 2020. Contact: (corresponding author).
This PaperHCQAll
Risk factors and outcome of COVID-19 in patients with hematological malignancies
José Luis Piñana, Rodrigo Martino, Irene García-García, Rocío Parody, María Dolores Morales, Gonzalo Benzo, Irene Gómez-Catalan, Rosa Coll, Ignacio De La Fuente, Alejandro Luna, Beatriz Merchán, Anabelle Chinea, Dunia De Miguel, Ana Serrano, Carmen Pérez, Carola Diaz, José Luis Lopez, Adolfo Jesús Saez, Rebeca Bailen, Teresa Zudaire, Diana Martínez, Manuel Jurado, María Calbacho, Lourdes Vázquez, Irene Garcia-Cadenas, Laura Fox, Ana I Pimentel, Guiomar Bautista, Agustin Nieto, Pascual Fernandez, Juan Carlos Vallejo, Carlos Solano, Marta Valero, Ildefonso Espigado, Raquel Saldaña, Luisa Sisinni, Josep Maria Ribera, Maria Jose Jimenez, Maria Trabazo, Marta Gonzalez-Vicent, Noemí Fernández, Carme Talarn, Maria Carmen Montoya, Angel Cedillo, Anna Sureda
Experimental Hematology & Oncology, doi:10.1186/s40164-020-00177-z
Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results: We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1-93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2-3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6-5.2, p < 0.0001); ECOG 3-4 (OR, 2.56, 95% CI 1.4-4.7, p = 0.003); neutropenia (< 0.5 × 10 9 /L) (OR 2.8, 95% CI 1.3-6.1, p = 0.01); and a C-reactive protein (CRP) > 20 mg/dL (OR 3.3, p < 0.0001). In multivariate analysis of 216 patients with very severe COVID-19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 0.42, 95% CI 0.2-0.89 and OR 0.31, 95% CI 0.11-0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did not show significant improvement in OM (OR 0.64, 95% CI 0.37-1.1, P = 0.1).
Authors' contributions JLP, and RM designed the study and drafted the manuscript. All authors participated in the revision of the manuscript. All authors read and approved the final manuscript. Ethics approval and consent to participate All patients gave their informed consent. Local ethics committee approved the study protocol (reference code 2020-113-1), registered by the Spanish Agency of Medicines and Health Products with the reference code GET-CLO-2020-01 and by the European Medicines Agency with the reference code EUPAS34365EBMT. Consent for publication The participants provided informed consent for the publication of the study. Competing interests The author(s) declare that they have no conflict of interests. Author details Piñana et al. Exp Hematol Oncol (2020) 9:21 • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year • At BMC, research is always in progress. Learn more Ready to submit your research ? Choose BMC and benefit from: es-death -by-up-to-one-third -in-hospi talis ed-patie nts-with-sever e-respi rator y-compl icati ons-of-covid - Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional..
Arons, Hatfield, Reddy, Kimball, James et al., Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility, N Engl J Med
Bhargava, Fukushima, Levine, Zhao, Tanveer et al., Predictors for severe COVID-19 infection, Clin Infect Dis, doi:10.1093/cid/ciaa674
Chen, Zheng, Liu, Yan, Xu et al., Plasma CRP level is positively associated with the severity of COVID-19, Ann Clin Microbiol Antimicrob
Cheson, Fisher, Barrington, Cavalli, Schwartz et al., Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association, J Clin Oncol
Chien, Martin, Gooley, Flowers, Heckbert et al., Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation, Am J Respir Crit Care Med
Dai, Liu, Liu, Zhou, Li et al., Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak, Cancer Discov, doi:10.1158/
Döhner, Estey, Grimwade, Amadori, Appelbaum et al., Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, doi:10.1182/blood-2016-08-733196
Erard, Chien, Kim, Nichols, Flowers et al., Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses, J Infect Dis
Fadel, Morrison, Vahia, Smith, Chaudhry et al., Henry Ford COVID-19 Management Task Force Early short course corticosteroids in hospitalized patients with COVID-19, Clin Infect Dis, doi:10.1093/cid/ciaa601
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Hao, Lian, Lu, Jia, Hu et al., Decreased B cells on admission was associated with prolonged viral RNA shedding from respiratory tract in Coronavirus Disease 2019: a case control study, J Infect Dis, doi:10.1093/infdis/jiaa311
Hoffmann, Kleine-Weber, Schroeder, Kruger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Jing, Ya, Xi, Pu, Zhaofeng et al., Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.017
Kolilekas, Loverdos, Giannakaki, Vlassi, Levounets et al., Can steroids reverse the severe COVID-19 induced 'cytokine storm, J Med Virol, doi:10.1002/jmv.26165
Kuderer, Choueiri, Shah, Shyr, Rubinstein et al., COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, Lancet, doi:10.1016/s0140-6736(20)31187-9
Kumar, Paiva, Anderson, Durie, Landgren et al., International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, doi:10.1016/S1470-2045(16)30206-6
Lapostolle, Schneider, Vianu, Dollet, Roche et al., Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVIDcall study, Intern Emerg Med, doi:10.1007/s11739-020-02379-z
Liang, Guan, Chen, Li, Xu et al., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol
Malard, Genthon, Brissot, Van De Wyngaert, Marjanovic et al., COVID-19 outcomes in patients with hematologic disease, Bone Marrow Transplant, doi:10.1038/s41409-020-0931-4
Martín-Moro, Marquet, Piris, Michael, Sáez et al., Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies, Br J Haematol, doi:10.1111/bjh.16801
Miyashita, Mikami, Chopra, Yamada, Chernyavsky et al., Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City, Ann Oncol, doi:10.1016/j.annonc.2020.04.006
Nishiura, Kobayashi, Miyama, Suzuki, Jung et al., Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19), Int J Infect Dis
Oken, Creech, Tormey, Horton, Davis et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol
Piñana, Pérez, Montoro, Hernani, Lorenzo et al., The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey, Bone Marrow Transplant
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Scarfò, Chatzikonstantinou, Rigolin, Quaresmini, Motta et al., COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus, Leukemia, doi:10.1038/s41375-020-0959-x
Shah, Ghantoji, Mulanovich, Ariza-Heredia, Chemaly, Management of respiratory viral infections in hematopoietic cell transplant recipients, Am J Blood Res
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal, J Heart Lung Transplant
So, Ro, Murakami, Imai, Jinta, High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series, Respirol Case Rep
Vikas, Sanjay, Rafi, Daniel, Mendel et al., Case fatality rate of cancer patients with COVID-19 in a New York Hospital System, Cancer Discov, doi:10.1158/2159-8290.CD-20-0516
Wan, Xiang, Fang, Zheng, Li et al., Clinical features and treatment of COVID-19 patients in northeast Chongqing, J Med Virol
Wang, Kang, Liu, Tong, Asymptomatic cases with SARS-CoV-2 infection, J Med Virol, doi:10.1002/jmv.25990
Wang, Van Oekelen, Mouhieddine, Valle, Richter et al., A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward, J Hematol Oncol
Wu, Chen, Cai, Xia, Zhou et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Internal Medicine, doi:10.1001/jamainternmed.2020.0994
Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China, JAMA Intern Med
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Yang, Liu, Zhou, Zhao, Zhao et al., The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis, J Infect
Yang, Yu, Xu, Shu, Liu et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1016/S2213-2600(20)30079-5
Yuan, Xu, Xia, Tao, Yin et al., Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis, Shock, doi:10.1097/SHK.0000000000001574
Zhang, Dong, Cao, Yuan, Yang et al., Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy, doi:10.1111/all.14238
Zhou, Yang, Wang, Hu, Zhang et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zou, Ruan, Huang, SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N Engl J Med
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop